Physiological Role of Plasmacytoid Dendritic Cells and Their Potential Use in Cancer Immunity

Table 1

Tumor	System	DC source	Protocol	References
EG7 T-cell lymphoma	Murine	Expanded in vivo (FLt3L), and sorted from BM	CpG-activated OVAp-pulsed pDCs/mDCs	Lou et al. [109] (2007)
K17-35-OVA melanoma	Murine	Isolated TIDCs from K17-35 melanoma	OVA-pulsed TIDCs	Preynat-Seauve et al. [110] (2006)
C26 colon Carcinoma	Murine	Isolated TIDCs from C26 tumor	TIDCs activated with CpG + anti-IL-10R (i.p.)	Vicari et al. [111] (2002)
M3 Melanoma	Murine	—	Topical application Imiquimod	Palamara et al. [46] (2004)
Melanoma cell lines	Human	Sorted from PBMC	pDCs activated with CD40L-transfected J558	Salio et al. [42] (2003)
Melanoma stage IIIb/c, IV	Human	—	CpG-7909 (s.c.) (ProMune)	Pashenkov et al. [112] (2006)

DCs, dendritic cells; pDCs, plasmacytoid DCs; BM, bone-marrow; OVAp, OVA peptide; TIDCs, tumor-infiltrating DCs (myeloid and plasmacytoid); PBMC, peripheral blood mononuclear cells.